FDA approves Erwinaze for acute lymphoblastic leukemia

The US Food and Drug Administration has granted market approval for a new treatment for a subset of patients suffering from acute lymphoblastic leukemia (ALL), the most commonly diagnosed childhood cancer and one with a generally very good prognosis.

Erwinaze's specific indication is for ALL patients previously treated with asparaginase and who develop hypersensitivity to Escherichia coli derived asparaginase.

Erwinaze is a so-called "asparaginase enzyme" which works by depleting asparagine levels in the bloodstream. In doing so, Erwinaze inhibits the growth of cells associated with ALL. Asparaginase products are derived from bacteria, and approximately 20% of patients develop hypersensitivity to modern products derived from E. coli, preventing their continued treatment.

Erwinaze helps the patient overcome that hypersensitivity so that they are able to complete the full course of asparaginase treatment.

Erwinaze is manufactured by EUSA Pharma. For more information, please visit the company web site.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap